论文部分内容阅读
目的探讨膜型/可溶型 MHC Ⅰ类链相关分子 A(MICA)及其受体 NKG2D 在骨肉瘤中的表达及其意义。方法采用免疫组织化学(LSAB法)检测膜型 MICA(mMICA)在43例骨肉瘤组织中的表达;用流式细胞仪检测上述病例中的16例患者外周血淋巴细胞 NKG2D 的表达;用 ELISA 法检测患者血清中可溶型 MICA(sMICA)的水平。结果骨肉瘤细胞广泛表达 mMICA(37/43),外周血淋巴细胞 NKG2D 的表达普遍下降,两者的表达水平均与骨肉瘤的分化呈正相关(P<0.05),与临床分期呈负相关(P<0.05)。检测16例骨肉瘤患者血清中 sMICA 含量,其中5例升高,且与骨肉瘤的远处转移及临床分期呈正相关(P<0.05)。结论 (1)骨肉瘤细胞表达 mMICA,外周血淋巴细胞NKG2D 的表达以及血清中 sMICA 的含量与骨肉瘤的分化及临床分期相关,因此可望作为骨肉瘤病理诊断和估计预后的生物学指标。(2)MICA-NKG2D 介导的免疫监视障碍可能促进了骨肉瘤的进展。
Objective To investigate the expression and significance of membrane-associated / soluble MHC class I chain-related molecule A (MICA) and its receptor NKG2D in osteosarcoma. Methods The expression of membrane MICA (mMICA) in 43 cases of osteosarcoma was detected by immunohistochemistry (LSCAS). The expression of NKG2D in 16 cases of peripheral blood lymphocytes was detected by flow cytometry. The level of soluble MICA (sMICA) in the patient serum was measured. Results Osteosarcoma cells widely expressed mMICA (37/43). The expression of NKG2D in peripheral blood lymphocytes generally decreased. The expression levels of both were correlated with the differentiation of osteosarcoma (P <0.05), and negatively correlated with clinical stage <0.05). The serum levels of sMICA in 16 cases of osteosarcoma were detected in 5 cases, which were positively correlated with the distant metastasis and clinical stage of osteosarcoma (P <0.05). CONCLUSIONS: (1) The expression of mMICA in osteosarcoma cells, the expression of NKG2D in peripheral blood lymphocytes and the level of sMICA in serum are correlated with the differentiation and clinical stage of osteosarcoma. Therefore, it is expected to be used as a biological indicator for pathological diagnosis and prognosis of osteosarcoma. (2) MICA-NKG2D-mediated immune monitoring disorder may promote the progress of osteosarcoma.